Sep 14, 2026 12:45PM
Sep 14, 2026 11:05AM
Sep 14, 2026 11:05AM
Aug 17, 2026 09:29AM
Aug 6, 2026 07:59AM
Jun 10, 2026 04:14PM
Jun 10, 2026 07:30AM Cullinan Therapeutics reports clinical trial data for autoimmune treatments
Jun 6, 2026 06:33AM
May 19, 2026 07:01AM
May 19, 2026 06:51AM
May 7, 2026 07:10AM
Apr 28, 2026 12:09PM
Apr 28, 2026 07:54AM
Apr 28, 2026 07:00AM FDA accepts drug application for zipalertinib lung cancer treatment
Mar 24, 2026 03:02PM
Mar 10, 2026 09:18AM
Mar 10, 2026 08:39AM
Feb 2, 2026 02:22AM
Jan 8, 2026 07:05AM
Dec 17, 2025 08:20AM
Dec 9, 2025 10:56AM Cullinan Oncology Inc. (CGEM) PT Raised to $28 at Leerink Partners
Dec 8, 2025 10:34AM
Nov 26, 2025 09:45AM
Nov 25, 2025 04:19AM
Nov 24, 2025 05:06AM
Nov 21, 2025 06:40AM
Nov 20, 2025 07:13AM
Nov 6, 2025 08:17AM Cullinan Oncology, Inc. (CGEM) Tops Q3 EPS by 18c
Sep 12, 2025 06:45AM
Sep 5, 2025 06:46AM
Aug 21, 2025 06:35AM
Aug 7, 2025 09:43AM
Jul 22, 2025 07:01AM
Jul 3, 2025 06:12AM
Jun 4, 2025 04:03PM Cullinan Therapeutics (CGEM) Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
May 8, 2025 05:11PM
Apr 29, 2025 07:03AM
Apr 16, 2025 07:00AM
Mar 3, 2025 06:02AM
Jan 30, 2025 06:39AM
Dec 12, 2024 01:17PM
Nov 14, 2024 10:01AM Cullinan Therapeutics (CGEM) Announces Preclinical Data for CLN-978
Oct 29, 2024 04:28PM
Oct 24, 2024 03:46AM
Oct 17, 2024 06:54AM
Oct 16, 2024 07:00AM
Sep 18, 2024 06:40AM
Sep 18, 2024 06:20AM
Sep 17, 2024 07:00AM Cullinan Therapeutics (CGEM) Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
Sep 16, 2024 08:51AM

466,776 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All